• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.

作者信息

Platzbecker U, Thiede C, Freiberg-Richter J, Röllig C, Helwig A, Schäkel U, Mohr B, Schaich M, Ehninger G, Bornhäuser M

机构信息

Med Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.

出版信息

Bone Marrow Transplant. 2001 Mar;27(5):543-6. doi: 10.1038/sj.bmt.1702819.

DOI:10.1038/sj.bmt.1702819
PMID:11313690
Abstract

Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recovery occurred. Unmanipulated G-CSF mobilized peripheral blood stem cells from an HLA-identical sibling donor were transfused and haematopoietic recovery was achieved in both recipients. Both of them are in continuing hematological remission with full donor chimerism 12 and 22 months after transplantation. Early treatment intensification with allogeneic cell therapy during marrow aplasia might cure high-risk AML patients who are unlikely to achieve remission with conventional chemotherapy protocols.

摘要

相似文献

1
Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.
Bone Marrow Transplant. 2001 Mar;27(5):543-6. doi: 10.1038/sj.bmt.1702819.
2
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.在接受异基因干细胞移植的难治性急性髓系白血病患者中,在氟达拉滨、阿糖胞苷和伊达比星化疗导致的血液学最低点给予白消安和氟达拉滨预处理方案:一项单臂前瞻性队列研究。
Medicine (Baltimore). 2015 Apr;94(15):e706. doi: 10.1097/MD.0000000000000706.
3
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.氟达拉滨联合每日一次静脉注射白消安作为异基因干细胞移植预处理的研究:药代动力学及早期临床结局分析
Biol Blood Marrow Transplant. 2002;8(9):468-76. doi: 10.1053/bbmt.2002.v8.pm12374451.
4
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.接受氟达拉滨、阿糖胞苷和安吖啶联合治疗后进行减低强度预处理及异基因干细胞移植的难治性急性髓系白血病患者预后的危险因素。
J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30.
5
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.克拉屈滨联合或不联合氟达拉滨,每日一次静脉注射白消安,作为进展期髓系白血病和骨髓增生异常综合征的移植前预处理方案。
Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900. doi: 10.1016/j.bbmt.2010.09.022. Epub 2010 Oct 11.
6
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.采用减低剂量预处理(FLAG+/-伊达比星)及第二次异基因干细胞移植治疗异基因骨髓移植后的复发。
Br J Haematol. 2001 Dec;115(3):622-9. doi: 10.1046/j.1365-2141.2001.03150.x.
7
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.在接受异基因造血干细胞移植的首次完全缓解的急性髓系白血病患者中,与白消安加环磷酰胺相比,白消安加氟达拉滨作为清髓性预处理方案:一项前瞻性多中心研究。
J Hematol Oncol. 2013 Feb 8;6:15. doi: 10.1186/1756-8722-6-15.
8
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.依托泊苷联合白消安加环磷酰胺作为急性髓性白血病患者干细胞移植预处理的剂量依赖性效应。
Bone Marrow Transplant. 2000 Oct;26(7):711-6. doi: 10.1038/sj.bmt.1702598.
9
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.采用减低强度预处理的异基因干细胞移植治疗慢性淋巴细胞白血病后的治疗相关死亡率及移植物抗白血病活性
Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905.
10
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.氟达拉滨与白消安的减低剂量预处理方案对比氟达拉滨与美法仑用于急性髓细胞白血病患者:欧洲血液与骨髓移植组急性白血病工作组的报告
Cancer. 2015 Apr 1;121(7):1048-55. doi: 10.1002/cncr.29163. Epub 2014 Nov 25.

引用本文的文献

1
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.中高危急性髓系白血病患者的造血细胞移植:来自随机 Study Alliance Leukemia(SAL)AML 2003 试验的结果。
Leukemia. 2015 May;29(5):1060-8. doi: 10.1038/leu.2014.335. Epub 2014 Dec 1.

本文引用的文献

1
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.异基因造血干细胞移植的剂量降低预处理:无需抗胸腺细胞球蛋白的持久植入。
Bone Marrow Transplant. 2000 Jul;26(2):119-25. doi: 10.1038/sj.bmt.1702500.
2
Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis.一名急性白血病患者化疗后骨髓再生障碍并进展为肺曲霉病,成功接受非清髓性异基因造血干细胞移植。
Blood. 1999 Nov 1;94(9):3273-6.
3
Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.
急性髓系白血病(AML)、转化型难治性贫血伴原始细胞增多(RAEB-t)和难治性贫血伴原始细胞增多(RAEB)中完全缓解时间对后续生存期及无病生存期的影响。
Blood. 2000 Jan 1;95(1):72-7.
4
Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia.影响难治性或复发性成人急性白血病患者异基因骨髓移植结局的因素。
Br J Haematol. 1999 Nov;107(2):409-18. doi: 10.1046/j.1365-2141.1999.01713.x.
5
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG.FLAG诱导缓解后难治性或复发性急性白血病的早期异基因移植
Leukemia. 1999 May;13(5):786-91. doi: 10.1038/sj.leu.2401406.
6
Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection.利用短串联重复序列标记的多重扩增和荧光检测快速定量混合嵌合体。
Bone Marrow Transplant. 1999 May;23(10):1055-60. doi: 10.1038/sj.bmt.1701779.
7
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.非清髓性干细胞移植和细胞疗法作为传统骨髓移植(伴有致死性细胞消减)的替代方法,用于治疗恶性和非恶性血液系统疾病。
Blood. 1998 Feb 1;91(3):756-63.
8
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).成人急性髓细胞白血病缓解后自体骨髓移植与强化化疗的比较。西部-东部急性髓细胞白血病研究组(GOELAM)。
Blood. 1997 Oct 15;90(8):2978-86.
9
Factors related to length of complete remission in adult acute leukemia.成人急性白血病完全缓解期长度的相关因素。
Cancer. 1980 Apr 15;45(8):2017-29. doi: 10.1002/1097-0142(19800415)45:8<2017::aid-cncr2820450806>3.0.co;2-c.
10
Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation.急性髓性白血病患者不进行异基因骨髓移植的原因。
N Engl J Med. 1992 Jan 16;326(3):156-60. doi: 10.1056/NEJM199201163260303.